Cure SMA: Basic Research Grant Program

UPCOMING DEADLINE: Cure SMA is accepting applications to support novel research that will enhance the understanding of spinal muscular atrophy (SMA) disease pathology at the molecular, cellular and biochemical level; generate key reagents and tools to facilitate drug development and clinical trials; and identify new therapeutic strategies for SMA in particular combination approaches. Award amount up to $75,000 per year for up to two (2) years. The application deadline is September 8, 2017 by midnight EST.

The UNC Office of Corporate and Foundation Relations has identified the following private funding opportunity:

Cure SMA: Basic Research Grant Program
http://www.curesma.org

Cure SMA is accepting applications to support novel research that will enhance the understanding of spinal muscular atrophy (SMA) disease pathology at the molecular, cellular and biochemical level; generate key reagents and tools to facilitate drug development and clinical trials; and identify new therapeutic strategies for SMA in particular combination approaches. Studies funded by this RFP will fall into one of the following areas:

  • Studies focused on the molecular and biochemical mechanisms regulating SMN expression or mediating SMN function. Results should lead to a better understanding of the requirements for SMN protein biologically. There is a particular interest in identifying genetic modifiers, upstream regulators of SMN expression / splicing / function, and downstream effectors of SMN functional activity, resulting in new drug targets for SMA.
  • Studies resulting in greater understanding of the pathophysiology of SMA, using well-validated animal or cellular models of the SMA. This includes focus on the tissue or timing requirements for SMN protein, the cellular autonomy of the disease in motor neurons and other cells, peripheral versus central manifestations of SMA, and others.
  • Studies focused on early proof-of concept assessment of novel therapeutic approaches for SMA in well-validated animal or cellular models of the disease or on progressing aspects of ongoing preclinical drug programs for SMA towards IND. Proposed SMN enhancing approaches should have advantage over current candidates or have the ability to be used in combination. Particular interest exists in non-SMN based approaches with the potential for combination use with SMN up-regulation strategies.
  • Work focused on generating research or clinical trial tools for SMA, such as new animal models, phenotypic cellular assays, activity assays for SMN function, biomarkers or outcome measures for clinical trials, and newborn screening protocols / technologies.

Cure SMA is a 510(c)(3) organization. Indirect costs cannot exceed 8%.

Application Deadline: September 8, 2017 (midnight ET). Award notification made in January 2018. Application Guidelines: http://www.curesma.org/research/for-researchers/funding-opportunities/basic-research-funding-opportunities/

The UNC Office of Corporate and Foundation Relations is available to provide assistance to UNC personnel pursuing privately funded opportunities. If you have any questions about this funding opportunity, please email cfr@unc.edu or phone 919.962.2867.

Filed under: